Search

Your search keyword '"Pfister, Herbert"' showing total 396 results
Start Over Author "Pfister, Herbert" Publication Type Academic Journals
396 results on '"Pfister, Herbert"'

2. Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study

Author

Bouwes Bavinck, Jan N., Feltkamp, Mariet C.W., Green, Adele C., Fiocco, Marta, Euvrard, Sylvie, Harwood, Catherine A., Nasir, Shaaira, Thomson, Jason, Proby, Charlotte M., Naldi, Luigi, Diphoorn, Janouk C.D., Venturuzzo, Anna, Tessari, Gianpaolo, Nindl, Ingo, Sampogna, Francesca, Abeni, Damiano, Neale, Rachel E., Goeman, Jelle J., Quint, Koen D., Halk, Anne B., Sneek, Carmen, Genders, Roel E., de Koning, Maurits N.C., Quint, Wim G.V., Wieland, Ulrike, Weissenborn, Sönke, Waterboer, Tim, Pawlita, Michael, and Pfister, Herbert

Published
2018
Full Text
View/download PDF

7. Resolution of novel human papillomavirus--induced warts after HPV vaccination

Author

Silling, Steffi, Wieland, Ulrike, Werner, Marko, Pfister, Herbert, Potthoff, Anja, and Kreuter, Alexander

Subjects
Vaccination -- Health aspects, Genomics -- Health aspects, Papillomaviruses -- Health aspects, Skin -- Health aspects, Health
Abstract

Human papillomaviruses (HPVs), small, double-stranded DNA viruses with a circular genome of ≅8,000 bp, are assigned to different genera and species on the basis of their major capsid protein gene [...]

Published
2014
Full Text
View/download PDF

27. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing

Author

Oette, Mark, Kaiser, Rolf, Daumer, Martin, Petch, Ruth, Fatkenheuer, Gerd, Carls, Horst, Rockstroh, Jurgen Kurt, Schmaloer, Dirk, Stechel, Jurgen, Feldt, Torsten, Pfister, Herbert, and Haussinger, Dieter

Subjects
Antiviral agents -- Patient outcomes, Antiviral agents -- Comparative analysis, Highly active antiretroviral therapy -- Patient outcomes, Highly active antiretroviral therapy -- Comparative analysis, HIV infection -- Drug therapy, Health
Abstract

Study is conducted to evaluate the efficacy of first-line highly active antiretroviral therapy (HAART) guided by genotypic resistance testing by comparing treatment outcomes of patients with drug-sensitive HIV to outcomes of patients with primary resistance. HAART guided by resistance testing had similar efficacy in patients with primary drug resistance as compared with patients with wild-type virus.

Published
2006

40. Evolution of raltegravir resistance during therapy

Author

Sichtig, Nadine, Sierra, Saleta, Kaiser, Rolf, Däumer, Martin, Reuter, Stefan, Schülter, Eugen, Altmann, Andre, Fätkenheuer, Gerd, Dittmer, Ulf, Pfister, Herbert, and Esser, Stefan

Published
2009

42. Natural History of Cutaneous Human Polyomavirus Infection in Healthy Individuals.

Author

Bopp, Luisa, Wieland, Ulrike, Hellmich, Martin, Kreuter, Alexander, Pfister, Herbert, and Silling, Steffi

Subjects
POLYOMAVIRUS diseases, MERKEL cell carcinoma, MERKEL cells, LOGISTIC regression analysis, POLYOMAVIRUSES, VIRAL load
Abstract

Several human polyomaviruses (HPyVs) were recently discovered. Merkel cell polyomavirus (MCPyV) induces Merkel cell carcinoma. HPyV6, HPyV7, and TSPyV have been associated with rare skin lesions in immunosuppressed patients. HPyV9, HPyV10, and Saint Louis Polyomavirus (STLPyV) have not been convincingly associated with any disease. The aim of this prospective study was to evaluate the cutaneous prevalence, persistence and viral load of HPyVs in healthy individuals. Eight hundred seventy forehead and hand swabs were collected from 109 volunteers 4–6 weeks apart (collection period-1). Fifty-nine participants were available for follow-up a decade later (collection period-2). HPyV-DNA prevalence and viral loads of MCPyV, HPyV6, HPyV7, TSPyV, HPyV9, HPyV10, and STLPyV were determined by virus-specific real-time PCRs. Risk factors for HPyV prevalence, short- and long-term persistence were explored by logistic regression analyses. Baseline prevalence rates were similar for forehead and hand: MCPyV 67.9/67.0%, HPyV6 31.2/25.7%, HPyV7 13.8/11.0%, HPyV10 11.9/15.6%, STLPyV 7.3/8.3%, TSPyV 0.9/0.9%, and HPyV9 0.9/0.9%. Short-term persistence in period-1 was found in 59.6% (MCPyV), 23.9% (HPyV6), 10.1% (HPyV7), 6.4% (HPyV10), 5.5% (STLPyV), and 0% (TSPyV and HPyV9) on the forehead, with similar values for the hand. Long-term persistence for 9–12 years occurred only for MCPyV (forehead/hand 39.0%/44.1% of volunteers), HPyV6 (16.9%/11.9%), and HPyV7 (3.4%/5.1%). Individuals with short-term persistence had significantly higher viral loads at baseline compared to those with transient DNA-positivity (p < 0.001 for MCPyV, HPyV6, HPyV7, and HPyV10, respectively). This was also true for median viral loads in period-1 of MCPyV, HPyV6, and HPyV7 of volunteers with long-term persistence. Multiplicity (two or more different HPyVs) was a risk factor for prevalence and persistence for most HPyVs. Further risk factors were older age for HPyV6 and male sex for MCPyV on the forehead. Smoking was not a risk factor. In contrast to MCPyV, HPyV6, HPyV7, and rarely STLPyV, polyomaviruses TSPyV, HPyV9, and HPyV10 do not seem to be long-term constituents of the human skin virome of healthy individuals. Furthermore, this study showed that higher viral loads are associated with both short- and long-term persistence of HPyVs on the skin. HPyV multiplicity is a risk factor for prevalence, short-term and/or long-term persistence of MCPyV, HPyV6, HPyV7, and HPyV10. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. Trends of prevalence of primary HIV drug resistance in Germany

Author

Sagir, Abdurrahman, Oette, Mark, Kaiser, Rolf, Däumer, Martin, Fätkenheuer, Gerd, Rockstroh, Jürgen Kurt, Knechten, Heribert, Schmutz, Günther, Hower, Martin, Emmelkamp, Jetske, Pfister, Herbert, and Häussinger, Dieter

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results